Study of CAP-1002 to benefit skeletal muscle function in boys and young men with Duchenne muscular dystrophy (DMD)

Trial Profile

Study of CAP-1002 to benefit skeletal muscle function in boys and young men with Duchenne muscular dystrophy (DMD)

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs CAP-1002 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2017 According to a Capricor Therapeutics media release, this trial is expected to begin in fourth quarter of 2017.
    • 15 Mar 2017 According to a Capricor Therapeutics media release, this trial is expected to begin in second half of 2017.
    • 26 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top